Acceleron Pharma Inc (XLRN) Receives Average Recommendation of “Hold” from Brokerages

Shares of Acceleron Pharma Inc (NASDAQ:XLRN) have earned a consensus recommendation of “Hold” from the twenty brokerages that are covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have given a buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $46.33.

A number of equities research analysts have recently weighed in on XLRN shares. Royal Bank of Canada reissued a “hold” rating on shares of Acceleron Pharma in a research note on Thursday, November 2nd. HC Wainwright boosted their target price on Acceleron Pharma from $57.00 to $62.00 and gave the company a “buy” rating in a research note on Tuesday, November 7th. Credit Suisse Group set a $51.00 target price on Acceleron Pharma and gave the company a “buy” rating in a research note on Tuesday, November 14th. Oppenheimer reissued a “hold” rating on shares of Acceleron Pharma in a research note on Tuesday, November 14th. Finally, BidaskClub raised Acceleron Pharma from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th.

In other Acceleron Pharma news, SVP Christopher Rovaldi sold 11,000 shares of the company’s stock in a transaction that occurred on Friday, January 12th. The stock was sold at an average price of $45.00, for a total transaction of $495,000.00. Following the transaction, the senior vice president now owns 35,701 shares in the company, valued at approximately $1,606,545. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jean George sold 105,122 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $35.73, for a total value of $3,756,009.06. Following the transaction, the director now owns 1,250 shares in the company, valued at approximately $44,662.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 146,021 shares of company stock worth $5,529,598. 3.90% of the stock is owned by company insiders.

Several hedge funds have recently bought and sold shares of the business. Parametric Portfolio Associates LLC grew its holdings in shares of Acceleron Pharma by 3.9% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 9,456 shares of the biopharmaceutical company’s stock worth $287,000 after acquiring an additional 355 shares during the period. California Public Employees Retirement System grew its holdings in shares of Acceleron Pharma by 6.7% during the 4th quarter. California Public Employees Retirement System now owns 22,300 shares of the biopharmaceutical company’s stock worth $946,000 after acquiring an additional 1,400 shares during the period. American International Group Inc. grew its holdings in shares of Acceleron Pharma by 8.1% during the 3rd quarter. American International Group Inc. now owns 21,487 shares of the biopharmaceutical company’s stock worth $802,000 after acquiring an additional 1,607 shares during the period. Nationwide Fund Advisors grew its holdings in shares of Acceleron Pharma by 8.8% during the 2nd quarter. Nationwide Fund Advisors now owns 24,737 shares of the biopharmaceutical company’s stock worth $752,000 after acquiring an additional 2,000 shares during the period. Finally, Quantbot Technologies LP grew its holdings in shares of Acceleron Pharma by 416.3% during the 3rd quarter. Quantbot Technologies LP now owns 2,917 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 2,352 shares during the period. Hedge funds and other institutional investors own 85.81% of the company’s stock.

Acceleron Pharma (XLRN) traded up $0.49 during midday trading on Wednesday, hitting $41.47. The stock had a trading volume of 304,000 shares, compared to its average volume of 315,141. Acceleron Pharma has a 12 month low of $24.37 and a 12 month high of $46.93. The company has a market cap of $1,853.73, a price-to-earnings ratio of -16.18 and a beta of 1.45.

TRADEMARK VIOLATION NOTICE: This piece of content was posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/14/acceleron-pharma-inc-xlrn-receives-average-recommendation-of-hold-from-brokerages.html.

Acceleron Pharma Company Profile

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Analyst Recommendations for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply